| Indication for CBD prescription | Domain of EQ-5D-5L | Baseline EQ-5D-5L scores, median (IQR) | Follow-up EQ-5D-5L scores, median (IQR) | P v alue |
|---|---|---|---|---|
| Non-cancer pain symptoms (n = 53) | Mobility | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 0.022 |
| Self-care | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 0.046 | |
| Usual activities | 3.0 (2.0 to 4.0) | 2.0 (1.0 to 3.0) | 0.007 | |
| Pain/discomfort | 3.5 (3.0 to 4.0) | 3.0 (2.0 to 3.0) | <0.001 | |
| Anxiety/depression | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) | 0.017 | |
| Mental health symptoms (n = 21) | Mobility | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 0.577 |
| Self-care | 1.0 (1.0 to 1.75) | 1.0 (1.0 to 1.0) | 0.096 | |
| Usual activities | 3.0 (2.0 to 3.0) | 1.0 (1.0 to 2.0) | 0.002 | |
| Pain/discomfort | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 2.0) | 0.039 | |
| Anxiety/depression | 4.0 (3.0 to 4.0) | 2.0 (1.5 to 3.0) | 0.002 | |
| Neurological symptoms (n = 11) | Mobility | 1.0 (1.0 to 3.0) | 1.5 (1.0 to 2.0) | 0.317 |
| Self-care | 1.0 (1.0 to 3.0) | 1.5 (1.0 to 2.0) | 0.317 | |
| Usual activities | 3.0 (1.75 to 4.0) | 2.5 (1.75 to 3.25) | 0.194 | |
| Pain/discomfort | 3.0 (1.5 to 3.5) | 3.0 (1.5 to 3.0) | 0.18 | |
| Anxiety/depression | 3.0 (2.0 to 3.0) | 1.5 (1.0 to 3.0) | 0.194 | |
| Cancer symptoms (n = 24) | Mobility | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 0.56 |
| Self-care | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 1.0) | 1 | |
| Usual activities | 2.0 (1.0 to 2.75) | 2.0 (1.0 to 3.0) | 1 | |
| Pain/discomfort | 3.0 (2.0 to 3.0) | 2.0 (1.0 to 2.5) | 0.047 | |
| Anxiety/depression | 2.0 (1.0 to 3.0) | 1.0 (1.0 to 2.0) | 0.11 |
Score of 1 = no problems, 2 = slight problems, 3= moderate problems, 4 = severe problems, 5 = extreme problems. P values are calculated from Wilcoxon rank sum tests. ‘Before’ scores taken at first consultation. ‘After’ scores taken after at least 3 weeks of cannabidiol intake.
CBD = cannabidiol. IQR = interquartile range.